Optimization of long-term treatment strategies in first episode patients with schizophrenia;Optimierung der pharmakologischen langzeitbehandlung ersterkrankter schizophrener patienten

PsychoNeuro

Volumn 30, Issue 11, 2004, Pages 615-619

  Riesbeck, Mathias ^a   Von Wilmsdorff, Martina ^a   Krohmer, Robert ^a   Wölwer, Wolfgang ^a   Bottlender, Ronald ^b   Möller, Hans Jürgen ^b   Gaebel, Wolfgang ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

First episode schizophrenia; Intermittent treatment; Long term treatment; Maintenance treatment; Typical and atypical neuroleptics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSENSUS; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH PROGRAM; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RATING SCALE; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TECHNIQUE;

EID: 9644281871     PISSN: 16119991     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-837067     Document Type: Article

References (20)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(suppl 4): 1-63
2. American Psychiatric Association. Quick reference to the American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2002. American Psychiatric Publishing: Arlington, 2002
3. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psych 2003; 60: 553-564
5. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Ed.). Behandlungsleitlinie Schizophrenie. Darmstadt, Steinkoppf 1998
6. Emsley R. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999; 25: 721-729
7. Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpeke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. First vs. multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002; 53: 145-159
8. Gaebel W, Janssen B, Riesbeck M. Modern treatment concepts in schizophrenia. Pharmacopsychiatry 2003; 36 (Suppl 3): 168-175
9. Gaebel W, Möller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, von Wilmsdorff M, Bottlender R, Klingberg S. Pharmacological long-term treatment strategies in first episode schizophrenia. Study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience (im Druck)
10. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 32: 1371-1376
11. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 21: 82-86
12. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64(Suppl 12): 1-100
13. Lehman AF, Steinwachs DM and the Co-Investigators of the PORT-Project. At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10
14. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extra pyramidal side-effects of the newantipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
15. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
16. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589
17. Marder RS, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. Schizophr Bull 2002; 28: 5-16
18. McEvoy J, Scheifler P, Frances A. The expert consensus guideline series: Treatment of schizophrenia. J Clin Psychiatry 1999; 60 (suppl 11): 3-80
19. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance: 43 (www.nice.org.uk) 2002
20. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson G. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79-87